Just Answers - Finance

Banks are in business to make money. They want to return as l

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

arge as a profit as they can to their stockholders. You may a

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ctually be better off buying their stock then putting your ha

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

rd-earned savings with them. But, I digress. The CD rates for

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

large banks such as World Savings, Bank of America, Citibank

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

, etc. are low because they have such a large base of low int

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

erest deposits such as savings accounts and checking accounts

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

Banks' profits are derived primarily from two sources. Fir

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

st, is fee income (checking account, ATM, call center fees, e

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

tc.). The second source is the spread they make on the diffe

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

rence between the savings and CD rates they pay on deposits a

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

nd the rates you pay for your loans through them. This isn't

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

a perfect example, but if the average rate they pay for thei

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

r combined deposits is 3.0% and the average loan rate is 6.0%

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

they are making a 300 Basis Point spread. On hundreds of mi

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

llions in loans, that is a lot of clams.

If you compare CD r

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ates across the country, the best rates are around 5.40% for

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

1Y. If the big banks had to pay that for all of their deposi

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

ts, they would only be making 60 Basis Points. They just can

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

't survive on that kind of a rate margin (or so they tell us)

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.justanswers.org.ua/article/101480/justanswers-Compare-CD-Rates-Across-The-Us.html">Compare CD Rates Across The Us</a>

BB link (for phorums):
[url=http://www.justanswers.org.ua/article/101480/justanswers-Compare-CD-Rates-Across-The-Us.html]Compare CD Rates Across The Us[/url]

It's tough to make a significant shift unless there is a burning desire to change. You must be inspired by the personal gain you see for yourself at the end of the career-change rainbow – and this gain must be greater than the pain of staying in place.

There are many differences between managing mature markets and new ones, where innovation plays a central role. In existing and mature markets companies follow the principles of good management. They protect intellectual property, try to be the first to market, invest in internal capabilities and superior technology.

1. Ask Ask people questions. There are two goals of asking questions. To find out what people are passionate about and to make sure that they know you care about what they think. If you are at a loss as to what motivates people, their passions are a great start.

Tags

Links

Just Answers - Compare CD Rates Across The Us

Related Articles: